Oral Contraceptive Pills: Access and Availability
This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.
The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
This brief provides an overview of oral contraception, discusses private insurance and Medicaid coverage, and reviews strategies to promote and expand women’s access to oral contraceptives.
Oral contraceptives are the most commonly used method of reversible contraception in the U.S. In July 2023, the FDA approved Opill, the first daily oral contraceptive pill to become available over the counter (OTC) without a doctor’s prescription. This issue brief provides an overview of OTC oral contraceptives and laws and policies related to insurance coverage.
This State and Federal Reproductive Rights Litigation tracker aggregates information about ongoing litigation regarding abortion bans and restrictions, FDA approval of Mifepristone (an abortion pill) and other federal regulations.
This brief examines efforts in 11 states to fill in funding gaps created by the 2025 federal budget reconciliation law, which prohibits federal Medicaid funding for reproductive-health care services provided by Planned Parenthood and other organizations that also provide abortion care.
Intrauterine devices (IUDs), along with implants, are known as long-acting reversible contraception (LARCs) because they can be used to prevent pregnancy for several years. This fact sheet reviews FDA-approved IUDs, as well as use, availability, and key issues in insurance coverage and financing of IUDs in the U.S.
Explore an overview of the Mexico City Policy, which, when in effect, requires foreign NGOs to certify that they will not “perform or actively promote abortion as a method of family planning” using funds from any source (including non-U.S. funds) as a condition for receiving U.S. government global health assistance.
The interactive map shows the increase in states with laws restricting abortion coverage in Medicaid and private insurance in 2010 compared to the present.
This analysis assesses the potential reach of the latest expansion of the Mexico City Policy, which is now part of the Promoting Human Flourishing in Foreign Assistance (PHFFA) Policy.
The Abortion in the U.S. Dashboard is an ongoing research project tracking state abortion policies and litigation following the overturning of Roe v. Wade.
This brief provides an overview of these legal challenges and summarizes the key positions of the plaintiffs and the defendants, Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS).
© 2026 KFF